Intranasal microemulsion of sildenafil citrate: In vitro evaluation and in vivo pharmacokinetic study in rabbits

AAPS PharmSciTech

Volumn 10, Issue 2, 2009, Pages 361-367

  Elshafeey, Ahmed H ^a   Bendas, Ehab R ^a   Mohamed, Osama H ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Bioavailability; Intranasal; Microemulsion; Nasal; Sidenafil citrate; Solubilization

Indexed keywords

ALCOHOL; BENZYL ALCOHOL; DIETHYLENE GLYCOL MONOETHYL ETHER; LABRASOL; OLEIC ACID; POLYSORBATE 20; SILDENAFIL; TAURODEOXYCHOLIC ACID; WATER; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CILIATED EPITHELIUM; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; EXPERIMENTAL RABBIT; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; NONHUMAN; PARTICLE SIZE; PH; RABBIT; RAT; SOLVENT EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; VISCOSITY; ABSORPTION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG EFFECT; EMULSION; INTRANASAL DRUG ADMINISTRATION; METABOLISM; NOSE MUCOSA; SOLUBILITY; TOAD;

ABSORPTION; ADMINISTRATION, INTRANASAL; ANIMALS; BIOLOGICAL AVAILABILITY; BUFONIDAE; EMULSIONS; HYDROGEN-ION CONCENTRATION; MALE; NASAL MUCOSA; PARTICLE SIZE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; RABBITS; SOLUBILITY; SULFONES; VISCOSITY;

EID: 67549104175     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9213-6     Document Type: Article

References (25)

1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, Mckinlay JB. Impotence and its medical and psychological correlates: Results of the Massachusetts male aging study. J Urol. 1994;151:54-61.
2. Johannes CB, Araujo AB, Felman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40-69 years old: Longitudinal results from the Massachusetts male aging study. J Urol. 2000;163:460-3.
3. NIH consensus development panel on impotence. Impotence. JAMA. 1993;270:83-90.
4. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: A critical review. J Clin Psychopharmacol. 1999;19:67-85.
5. Doggrell S. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction? Int J Impot Res. 2007;19:281-95.
6. Boolell M, Allen MJ, Ballard SA. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erection dysfunction. Int J Impot Res. 1996;8:47-52.
7. Rajagopalan P, Mazzu A, Xia C, Dawkins R, Sundaresan P. Effect of high-fat breakfast and moderate-fat evening meal on pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol. 2003;43:260-67.
8. Deveci S, Peskircioglu L, Aygun C, Tekin MI, Dirim A, Ozkardes H. Sublingual sildenafil in the treatment of erectile dysfunction: Faster onset of action with less dose. Int J Urol. 2004;11:989-92.
9. Richter T, Keipert S. In vitro permeation studies comparing bovine nasal mucosa, porcinecornea and artificial membrane: Androstenedione in microemulsions and their components. Eur J Pharm Biopharm. 2004;58:137-43.
10. Su KSE, In "Encyclopedia of Pharmaceutical Technology", edited by J. Swarbrick, and J. C. Baylan, Marcel Dekker, Inc. 175-201 (1993).
11. Noach A, Hurni MA, De Boer AG, Breimer DD, In Drug Absorption Enhancement. Concept, Possibilities, Limitations and Trends, Ed.: Harwood Academic Publishers: Chur, Vol. 3, 1994, p. 291-324.
12. Haecker R, Kampfe E, Mattern C. Androgenic substitution for the ageing male by nasal administration of a precursor of testosterone. Geneve: Congress: Healthy Ageing of Male, 1998.
13. •• gren's syndrome. Ann NY Acad Sci. 1999;876:312-24.
14. Tenjarla SN. Microemulsions: An overview and pharmaceutical applications. Critical Reviews ™ in Therapeutic Drug Carrier Systems. 1999;16:461-521.
15. Lieberman HA, Rieger MM, Banker GS. Pharmaceutical dosage forms: Disperse systems, second ed, Vol 1. New York: Marcel Decker, 1996, pp. 211-281, 315-70.
16. Kovarik JM, Muller EA, Van Bree JB, Tetzloff W, Kathz K. Reduced inter- and intra-individual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci. 1994;83:444.
17. Behl CR, Pimplaskar HK, Sileno AP, deMeireles J, Romeo VD. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Del Rev. 1998;29:89-116.
18. Zaki N, Awad G, Mortadaa N, Abd ElHady S. Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci. 2007;32:296-307.
19. Hussain A, Foster T, Hirai S, Kashihara T, Batenhorst R, Jones M. Nasal absorption of propranolol in humans. J Pharm Sci. 1980;69:1240-43.
20. Chien YW. Nasal drug delivery systems. In: Swacrbrick J, editor. Novel drug delivery systems. New York: Marcel Dekker, 1992, pp. 139-96.
21. Knoester PD, Jonker DM, Van der Hoeven RTM, Vermeij TAC, Edelbroek PM, Brekelmans GJ, de Haan GJ. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br J Clin Pharmacol. 2002;53:501-7.
22. Jiang XG, Cuii JB, Fang XL, Wei Y, Xi NZ. Toxicity of drugs on nasal mucocilia and the method of its evaluation. Acta Pharm. Sin. 1995;30:848-53.
23. Guide for the Care and Use of Laboratory Animals #86-23. Bethesda, MD: National Institutes of Health. (1985).
24. Hussain AA, Dittert LW. Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction. United States Patent. 6,200,591 (2001).
25. Smolinske SC. Handbook of food, drug, and cosmetic excipients. Boca Raton, FL. CRC Press, 1992, pp. 47-54.